Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414733 · ClinicalTrials.gov registry record · Phase 1
HER-2 B Cell Peptide Vaccine
A Phase 1 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, sponsored by Pravin T.P Kaumaya.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT06414733: Recruiting Phase 1 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, sponsored by Pravin T.P Kaumaya.
NCT06414733 is a Phase 1 study of Metastatic Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Pravin T.P Kaumaya. The registered enrollment target is 42 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414733, a Phase 1 study of Metastatic Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Pravin T.P Kaumaya.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center - Indianpolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
What NCT06414733 shows while recruiting
NCT06414733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower).
The record links to 5 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720 is the first listed.
NCT06414733 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06414733 about?
NCT06414733 is a clinical study titled "HER-2 B Cell Peptide Vaccine". This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT06414733?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-01-17. Estimated completion is 2030-12-31.
What conditions does trial NCT06414733 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, Metastatic Gastrointestinal Carcinoma, EGFR Overexpression.
What interventions are being tested in trial NCT06414733?
The interventions under investigation include: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06414733?
This trial is sponsored by Pravin T.P Kaumaya, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414733 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06414733's enrollment target sits among peer trials
42 88th of 139 higher than 51 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI